摘要
Objective:The aim of this study was to investigate the clinical value and relevance on the serum β2-microglobulin(β2-MG) of patients with thyroid cancer.Methods:One thousand and two normal cases,95 thyroid cancer patients and 243 nodular goiter patients were selected to measure serum β2-MG levels using double-antibody sandwich enzyme-linked immunosorbent assay(ELISA).Results:The positive rate of 7.78% in normal population(78/1002) and 31.57% in thyroid cancer patients(30/95).There were significant differences between the normal population and thyroid cancer patients(χ2 = 55.352;P = 0.000).The positive rate of 7.81% in nodular goiter patients(19/243) and there were no significant differences between the normal population and nodular goiter patients(χ2 = 0.0004;P = 0.986),but significant differences between nodular goiter patients and thyroid cancer patients(χ2 = 31.106;P = 0.000).Meanwhile,the significant difference of the positive rate existed in between the various pathological types of thyroid cancer(χ2 = 10.015;P = 0.007),anaplastic thyroid cancer patients with the highest positive rate and The significant difference was found between the positive lymph node metastasis groups and negative lymph node metastasis groups(χ2 = 4.441;P = 0.035),the presence of distant metastasis group and absence of distant metastasis group(χ2 = 9.795;P = 0.002).Conclusion:Serum β2-MG levels and prognosis of thyroid cancer patients was negatively correlated.It showed important clinical value to detect the level of β2-MG in the early diagnosis,prognosis and the clinical observation for thyroid cancer patients.
Objective： The aim of this study was to investigate the clinical value and relevance on the serum β2-microglobulin （β2-MG） of patients with thyroid cancer. Methods： One thousand and two normal cases, 95 thyroid cancer patients and 243 nodular goiter patients were selected to measure serum β2-MG levels using double-antibody sandwich enzyme-linked immunosorbent assay （ELISA）. Results： The positive rate of 7.78% in normal population （78/1002） and 31.57% in thyroid cancer patients （30/95）. There were significant differences between the normal population and thyroid cancer patients （X2 = 55.352; P = 0.000）. The positive rate of 7.81% in nodular goiter patients （19/243） and there were no significant differences between the normal population and nodular goiter patients （X2 = 0.0004; P = 0.986）, but significant differences between nodular goiter patients and thyroid cancer patients （x2 = 31.106; P = 0.000）. Meanwhile, the significant difference of the positive rate existed in between the various pathological types of thyroid cancer （X2 = 10.015; P = 0.007）, anaplastic thyroid cancer patients with the highest positive rate and The significant difference was found between the positive lymph node metastasis groups and negative lymph node metastasis groups （x2 = 4.441; P = 0.035）, the presence of distant metastasis group and absence of distant metastasis group （X2 = 9.795; P = 0.002）. Conclusion： Serum β2-MG levels and prognosis of thyroid cancer patients was negatively correlated. It showed important clinical value to detect the level of β2-MG in the early diagnosis, prognosis and the clinical observation for thyroid cancer patients.
